Enzo Biochem Inc (FRA:EZB)

€ 0.68 -0.005 (-0.73%) Market Cap: 36.34 Mil Enterprise Value: -6.62 Mil PE Ratio: 0 PB Ratio: 0.79 GF Score: 43/100

Q1 2023 Enzo Biochem Inc Earnings Call Transcript
Dec 13, 2022

€1.53 (-11.56%)

Earnings
Q4 2022 Enzo Biochem Inc Earnings Call Transcript
Oct 14, 2022

€2.14

Earnings
Q3 2022 Enzo Biochem Inc Earnings Call Transcript
Jun 10, 2022

€2.1 (-5.41%)

Earnings
Enzo Biochem Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript
Mar 22, 2022
Q2 2022 Enzo Biochem Inc Earnings Call Transcript
Mar 14, 2022

€2.78 (-3.47%)

Earnings
Q1 2022 Enzo Biochem Inc Earnings Call Transcript
Dec 15, 2021

€3.06 (-1.92%)

Earnings
Q4 2021 Enzo Biochem Inc Earnings Call Transcript
Oct 12, 2021

€3.22 (-9.04%)

Earnings
Q3 2021 Enzo Biochem Inc Earnings Call Transcript
Jun 09, 2021

€2.64 (+4.76%)

Earnings
Q2 2021 Enzo Biochem Inc Earnings Call Transcript
Mar 15, 2021

€2.38 (-2.46%)

Earnings
Enzo Biochem Inc Annual Shareholders Meeting Transcript
Jan 04, 2021
Q1 2021 Enzo Biochem Inc Earnings Call Transcript
Dec 09, 2020

€1.97 (+0.51%)

Earnings
Q4 2020 Enzo Biochem Inc Earnings Call Transcript
Oct 13, 2020

€2.08 (+6.67%)

Earnings
Q3 2020 Enzo Biochem Inc Earnings Call Transcript
Jun 08, 2020

€2.26 (-13.08%)

Earnings
Q2 2020 Enzo Biochem Inc Earnings Call Transcript
Mar 06, 2020

€1.96 (-0.51%)

Earnings
Q1 2020 Enzo Biochem Inc Earnings Call Transcript
Dec 10, 2019

€2.34 (-2.50%)

Earnings
Q4 2019 Enzo Biochem Inc Earnings Call Transcript
Oct 15, 2019

€2.98 (-0.67%)

Earnings
Q3 2019 Enzo Biochem Inc Earnings Call Transcript
Jun 11, 2019

€3.35 (+11.67%)

Earnings
Q2 2019 Enzo Biochem Inc Earnings Call Transcript
Mar 12, 2019

€2.73 (+0.37%)

Earnings

Enzo Biochem Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript

Mar 22, 2022 / 07:00PM GMT

Release Date Price: €2.72 (+0.74%)

Transcript

Harrison Schrage

KeyBanc Capital Markets - Analyst

Hello and welcome to KeyBanc's 2022 Healthcare Conference. My name is Harrison Schrage, and I'm an equity research associate on Paul Knight's life sciences team here in New York. Here, we'll be discussing Enzo Biochem with CEO Hamid Erfanian and CFO Dave Bench.

If anyone in the audience has any questions, please submit them in the question box below. We'll probably have time for a little bit of Q&A near the end of the session. So I'll be monitoring that. I guess, yeah, let's just dive right into it.

So Hamid and Dave, also, if you guys could just provide like a brief history of Enzo and kind of just a little bit of an overview of your segments today.

Hamid Erfanian

Enzo Biochem, Inc. - CEO

Okay, that sounds great. Again, this is Hamid Erfanian. Welcome and thank you for joining us. I've been with Enzo since November 8, 2022 -- in 2021. So that's going about four months. I'm excited to be here.

Brief overview of Enzo, the best way that I can share with you is it's a biotech

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.